Abstra ct Backgro und: Heart failure (HF) is a common complication of cardiovascular diseases, and patients with HF remain largely under the care of primary care physicians (GPs -blockers (bisoprolol, carvedilol, nebivolol) (Cardiol J 2013; 20, 4: 356-363) 
Introduction
Heart failure (HF) is currently one of the most common and rising chronic diseases in developed countries. Total percentage of people with HF reaches 0.4-2% in Europe [1] and among people over the age of 75 it exceeds 10% [2] . In European Union countries the number of patients surpasses 15 million [3] and in Poland 1 million [4] . The study conducted in Poland in 2005 showed that most of Agnieszka Parnicka et al., GPs' awareness of chronic heart failure the patients with HF were under the care of primary care physicians (GPs) [5] .
The randomized, multicentre study SHAPE (the Study group on Heart Failure Awareness and Perception in Europe), carried out in 2008, also in Poland, showed poor adherence to guideline-recommended management strategies of HF, especially in the group of internists, geriatricians and GPs [6] . Similarly, recently published data of the Polish study, assessing the knowledge of 125 GPs, demonstrated that a satisfactory adherence to Polish guidelines-management of hypertension characterized 51% GPs [7] .
To our best knowledge, the relationship between a physician's age or years of professional experience has not been studied yet. Therefore, the aim of the presented study is to assess whether age of GPs is associated with their knowledge of chronic HF guidelines and is it related with therapeutic decision making in management of HF patients.
Methods
In 2008, a Polish nationwide education project for GPs about guideline-recommended management strategies in HF was conducted. It was a multicenter project, and a training program was developed in collaboration with The College of Family Physicians in Poland.
The trainings' schedule and agenda were available on the offi cial website of the College. The project was also promoted in the educational journal of Polish GPs and in a newsletter sent periodically to GPs. Recruitment for participation in training was conducted through the website.
The courses were conducted in 15 provinces in Poland from 15 September to 30 November 2008, and the study involved 872 GPs. At the beginning of each training, participants fi lled out a standardized questionnaire consisting of 19 questions -5 of them related to the diagnosis and 14 to the recommendations from 2008 on the treatment of chronic HF. There were 16 single and 3 multiple choice type questions with predefi ned answers.
The answers were assessed according to the guidelines of European Society of Cardiology (ESC) published in 2005 [8] . The analysis was performed in three age-groups of physicians: 24-39 years (n = 142), 40-55 years (n = 316) and 56 and more years old (n = 156).
The database management and statistical analysis were performed using SAS software, version 9.2 (SAS Institute Inc, Cary, NC) licensed to the Jagiellonian University.
Descriptive statistics involved mean ± standard deviations (SD) and percentages. Distribution of continuous variables was determined by Shapiro-Wilk test. One-way ANOVA was used for comparisons of continuous variables between the age-groups and contingency coeffi cient (C c ) to determine association between categorical variables.
Results
Out of 872 GPs who attended all training courses, 614 completed and returned the questionnaires (70%). The mean age of the respondents was 48.0 ± 11.5 ranging from 24 to even 90 years, 76% of them were women.
Heart failure diagnosis and classifi cation
More than 96% of GPs from each age-group indicated echocardiography as a procedure essential to diagnose HF ( Table 1 ). The oldest physicians more frequently than the younger ones pointed to the role of chest X-ray (63%, p < 0.001) and electrocardiography (32%, p < 0.001) in exclusion of systolic HF. On the other hand, the younger physicians signifi cantly more likely indicated left ventricular ejection fraction (LVEF), above 50%, without mitral insuffi ciency as exclusion criterion (Table 1) .
Only 23% of GPs recognized and declared the application of current HF classifi cation as systolic and diastolic (with preserved LVEF). This classifi cation has not been used by 72% of physicians, despite the knowledge of this classifi cation. However, the New York Heart Association (NYHA) scale was used on everyday practice by almost all the GPs (94%); only 1% of GPs did not apply any of these classifi cations.
Heart failure pharmacotherapy
For HF patients with NYHA class I or II and sinus rhythm, angiotensin converting enzyme inhibitors (ACE-I), angiotensin II receptor blockers (ARB), b-blockers, and diuretics were recommended by physicians from different age groups with similar frequency (Table 2 ). Older physicians signifi cantly more frequently indicated spironolactone, digitalis, and calcium channel blockers as preferred drugs (Table 2) .
In patients with advanced HF (NYHA class III to IV), the respondents favored diuretics, spironolactone and digitalis without signifi cant differences between the age-groups (Table 2) . Moreover, older GPs, compared to younger, declared less frequent use of ARB and b-blockers. Younger GPs were more likely to use sartans in their patients with HF because of intolerance of ACE-I (age 24-39: 97.0%; 40-55: 89.4%; 56-90 : 87.1%), whereas older GPs more often administered this class of drugs as a continuation of therapy (age 24-39: 22.0%; 40-55: 29.9%; 56-90: 36.7%).
Among ACE-I recommended by the ESC guidelines were enalapril, captopril and lisinopril. The proper recommended dose of enalapril (10 mg twice a day) was indicated by 17.0% of GPs at age 24-39; 32.1% at age 40-55; 13.7% at age 56-90 (p = 0.016). The target dose of captopril (25-50 mg three times a day) indicated 13.4% at age 24-39; 21.5% at age 40-55 and 5.3% at age 56-90. Lisinopril (5-20 mg twice a day) had been chosen in a optimal dose by 13.6% GPs aged 24-39, 24.4% aged 40-55 and 9.9% aged 56-90. Use of maximal guideline-recommended doses of ACE-I in HF patients declared 41.1% of young, 37.1% of middle-aged and 29.6% of older GPs (Table 3 ). In general, more than half of the youngest GPs and approximately 78% GPs from the oldest group adjusted dosage of ACE-I according to HF severity (Table 3) .
Declared use of b-blockers, recommended by the guidelines inversely correlated with the age of the respondents. The percentage (respectively for three age categories from the youngest to the oldest) was for: bisoprolol: 97.9%; 93.2%; 88.1%; p = 0.005; carvedilol: 95.7%; 91.9%; 87.4%; p = 0.036; metoprolol: 90.1%; 89.6%; 84.1%; p = 0.17 and fro nebivolol: 58.2%; 44.3%; 50.3%; p = 0.023. Atenolol has been indicated by 15.2% of the oldest GPs, 13.0% of middle-aged and 2.1% of the youngest ones (p < 0.001), whereas propranolol was used respectively by 6.6%, 5.7% and 1.4% GPs (p = 0.077). As for the maximum recommended doses of b-blockers GPs most often pointed to: bisoprolol 10 mg daily, carvedilol 2 × 25 mg per day, metoprolol 200 mg and nebivolol 10 mg per day. The younger GPs signifi cantly more frequently indicated the proper target doses of the b-blockers than the older (Fig. 1) . Most older GPs declared to adjust the dose of b-blockers according to the severity of HF and blood pressure level, while the youngest GPs more frequently declared use of maximum doses of b-blockers (Table 3) .
Almost all of the respondents (95.7%) recommended diuretics in patients with fluid retention and up to 43.0% of GPs used them in all patients with HF, more frequently middle--aged physicians (40.1%) and older physicians (59.0%) compared with the young ones (29.8%, p < 0.001). Diuretics, as the first drug for the treatment of HF, were chosen by 46.9% of GPs at age 56-90, 33.7% of GPs at age 40-55, and by 17.9% of the youngest GPs (p < 0.001). The physicians usually started treatment with low doses of loop diuretics (79.0%) or low doses Table 2 . Physicians' declarations about pharmacotherapy of their patients with systolic heart failure. Table 3 . Physicians' perception of ACE-I and beta-blockers management in their patients with heart failure (HF). of thiazide diuretics (78.2%), and there were no significant differences in age-group comparisons. The respondents most often declared b-blockers, ACE-I and sartans as drugs with potential to prolong the life of patients with HF (Table 4) . The younger GPs more often recommended digitalis as the drug reducing HF symptoms, whereas the older GPs more often believed that digitalis can improve prognosis (Table 4) . About half of the surveyed GPs had a diffi culty in defi ning the role of calcium channel blockers in the treatment of HF. Apart from that, 15% of the oldest GPs expected that long-lasting nitroglycerine will improve prognosis of patients with HF (Table 4 ).
Discussion
Our study indicated generational differences among Polish GPs in approach to the existing guideline recommendations on HF diagnosis and Echocardiography criteria of diagnosis HF were frequently more indicated by younger physicians, while the oldest physicians were more likely to base their diagnoses on chest X-ray and electrocardiography results. In the IMPROVEMENT project (1999) (2000) , the fi rst large study assessing HF patients management, only 18% of GPs indicated echocardiography as a necessary diagnostic procedure in HF [9] . Similarly, in a European Heart Failure Study (EHFS) I and II, conducted from 2000 to 2001 in 24 European countries, it was found that in some centers cardiac ultrasound was performed in 20-30% patients with suspected or diagnosed HF, and the average rate of echocardiography was 58% [10] . Our previously published data has shown that approximately 50% of HF patients in primary settings were not examined by echocardiography [11] .
More than 10 years after the IMPROVEMENT study, our results show that 96% of GPs are aware of the role of echocardiography in the diagnostic process of HF. However, almost half of the respondents (mainly older GPs) incorrectly exclude HF on the basis of normal cardiac size in patients' chest X-ray, as normal results of radiological examination of the chest are present in 1/3 of patients with HF, such as with preserved left ventricular function or in restrictive cardiomyopathy [12] . In recently published Italian study from 2011, 1078 GPs under the age of 40 were the group which could choose the most accurate diagnoses and treatment of cardiovascular diseases [13] .
We also demonstrated that treatment strategies declared by younger doctors are more consistent with ESC guidelines. Physicians' awareness and their compliance with guideline-recommended strategies of HF pharmacotherapy has signifi cantly improved within the last 10 years. Beginning from the aforementioned IMPROVEMENT study, ACE-I were used only in 65% of patients with HF and b-blockers in 34% of them and generally their dosage was insuffi cient [9] [10] [11] [12] [13] [14] . The study EHFS I and II revealed that among patients with suspected or previously diagnosed HF, ACE-I were used only in 62% and b-blockers only in 37% of the patients [10] . In the same study 90% of patients with LVEF below 40% were receiving ACE-I, but b-blockers were used only in 49% of them.
In our previously published data from the POLKARD study, ACE-I were taken by 81.0% and b-blockers by 68.3% of HF patients treated by GPs [11] . Based on physicians' declaration, presented in this study, the GPs awareness of HF pharmacotherapy and their compliance with guidelines seems to improve systematically.
The SHAPE study has shown that 62% GPs in Poland (in comparison to 42% GPs in Europe) declared to prescribe ACE-I in patients with HF [6] . In comparison, 78% of cardiologists and 79% of internists and geriatricians in Poland declared to use ACE-I in over 90% of patients with HF [6] .
A cross-sectional analysis that was performed with the data of 167 HF cases with documented left ventricular systolic dysfunction, enrolled in 37 GP practices in Germany showed that the proportion of target doses reached for ACE-I/sartan was 16% and for b-blockers only 8% [15] . When adjusted for relative contraindications, the percentage of target doses increased to 49% and 46%, respectively. These data are comparable with our physicians' declarations in regards to use of maximal doses of the b-blocker, but maximal doses, both of ACE-I and b-blockers, were more likely used by younger physicians than the older.
In retrospective cohort study performed in 163 GPs in Great Britain (2001) (2002) (2003) (2004) (2005) (2006) , on 9311 HF patients only 36.6% were prescribed a b-blocker and 68% of them had a b-blocker currently recommended in ESC guidelines [16] . In our study, most physicians declared the use of guideline--recommended b-blockers, however up to 15% of physicians (mainly older GPs) continue to prescribe older class agents.
High position among the drugs recommended by GPs took diuretics. As many as 80.7% of older physicians declared to prescribe these drugs already in NYHA class I and II. The MAHLER study (Medical Management of Chronic Heart Failure in Europe and its Related Costs) assessed the treatment of patients by the randomly selected European cardiologists. In this study diuretics were most commonly prescribed and 79% of patients with HF, mainly class NYHA II and III, were receiving them [17] .
In comparison to guidelines given by European and Polish Society of Cardiology, our study showed that GPs declared to prescribe spironolactone very often in HF cases. Half of older GPs declared the use of spironolactone in HF classifi ed as NYHA I and II, while it should be limited in this stage to postinfarctial HF patients only. Earlier Polish study (2004, PolKARD-SPOK) revealed that 21.9% patients with HF in class NYHA II-IV were treated with spironolactone [18] . It is possible that within a few years between these two studies the GPs' awareness increased. However, we cannot compare
